WO2006109867A1 - ピラゾロ[1,5-a]ピリジン誘導体またはその医学上許容される塩 - Google Patents
ピラゾロ[1,5-a]ピリジン誘導体またはその医学上許容される塩 Download PDFInfo
- Publication number
- WO2006109867A1 WO2006109867A1 PCT/JP2006/307890 JP2006307890W WO2006109867A1 WO 2006109867 A1 WO2006109867 A1 WO 2006109867A1 JP 2006307890 W JP2006307890 W JP 2006307890W WO 2006109867 A1 WO2006109867 A1 WO 2006109867A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituted
- optionally substituted
- atom
- ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a novel pyrazomouth [1, 5-a] pyridine derivative or a medically acceptable salt thereof, a medical product containing each of them, and MAPKAP-K 2 (mitogen-activated) containing them as active ingredients Protein kinase activated protein kinase 2) Inhibitors, and novel intermediates thereof
- the present invention also includes those components ⁇ ) as a 3 ⁇ 43 ⁇ 4) component, neuropathy '14 / neurologic disorder (including dementia), rn ⁇ .autoimmune tt ⁇ disease, fracture »bone disorder, inflammation collapse Diseases, «, Diabetes, Cancer, Ischemic re- '« Flow disorders, Angiogenic disorders, Soil, Moon gourd, Angiogenesis, Asthma and / or Chronic obstructive city disease (COPD) About.
- '' Background technology includes those components ⁇ ) as a 3 ⁇ 43 ⁇ 4) component, neuropathy '14 / neurologic disorder (including dementia), rn ⁇ .autoimmune tt
- MAPKAP-K2 mitogen-activated proteinase-activated proteinase 2 is a serine / threatening nin kinase, p 3 in the stress-induced MAP K pathway
- This p38 kinase pathway is a variety of stress-related cells such as heat, ultraviolet light, bacterial lipopolysaccharide, and pro-inflammatory cytokines! It is activated by stimulation. This conversion leads to transcription and phosphorylation of the open platform factor, affecting cell division, apoptosis, cell differentiation, inflammation and cell invasion (Martin-B 1 anco, Bioessays 22 , 6
- p38 kinase itself activates many protein kinases other than MA PKAP kinase, such as * Mnkl / 2, PRA :, and IvlSK1 ( Figure 1). This g3 ⁇ 4 is particularly important for the discovery of new anti-inflammatory drugs.
- Selective inhibitors of p38 kinase are effective in suppressing pro-inflammatory cytokines in both cell-based and animal models of chronic inflammation (Lee et al., I mm unopha rma col ogy 47, 185-201 (2000)).
- p38 kinase knockout mice are embryonic iclet ha 1. Such embryo-derived cells have been proven to have many abnormalities with regard to the three detailed answers.
- MAPKAP-K2 makes the nucleus of unstimulated cells, cell force; when stimulated, it then moves to the cytoplasm.
- This kinase is known to phosphorylate many transcription factors, as well as cytosolic proteins, such as heat shock proteins involved in cytoprotection, and 5-lipoxygenase involved in inflammation (Stokoe FEBS Lett. 313, 307-313 (1992)), Werz et al., Pr o c., Natl. Ac a d. S ci. USA 97, 5261-5266 (2000)), He i ndenr eich et al., J.
- MAPKAP-K2 is the only p38 kinase substrate that has been identified with a special function.
- MAPKAP-K 2 special 3 ⁇ 4W in the mediation of flame ⁇ it answers, MAPKAP-K
- MAPKAP-K2 is thought to modulate the SIR and / or stability of the important pro-inflammatory cytokine mRNA. This is thought to be because MAPK AP-K2 phosphorylates proteins that bind to AU-rich elements found in the non-SIR region of these cytokines. The identification of these proteins is currently under study. .
- MAPKAP-K2 force 3 ⁇ 414 has been reported to repair DNA abnormalities induced by ultraviolet rays (Isa a c A. Manke et al., Mo 1 e c u 1 a r C e l l 17,
- Inhibiting g1 ⁇ 2 of MAPKAP-K2 may not be able to recover DNA damage, depending on the type of cancer cell, and may die.
- MAPKAP- ⁇ 2 ⁇ and neurological and neurological disorders including dementia, sepsis, autoimmune complications, debilitating bone disorders, inflammation, complications, diabetes, cancer, Disorders, Angiogenic Disorders, Defects, Obesity, Angiogenesis, Asthma and / or ⁇ 'Occluded Obstructive Pill Disease (COPD)).
- MAPKAP-K2 inhibitor IJ includes W02004 / 054504, W02004 / 0 54505, W02004 / 055015, WO 2004/055019, WO 2004/058176, W02004 / 058762, WO 2004/099127, WO 2005/009370 W02005 / 007092, WO 2004/076458, WO 200 4/081013 is known, but is structurally different from the compound of the present application.
- Pirazo mouth [1, 5-a] Pyridi ⁇ ! Conductors are W02004 / 026872, WO 2005/028445 and "WO 2005/077948.
- R 3 is a hydroxyl amino group in a compound disclosed in ⁇ 2005/077948, for example, only in a methyl group.
- the object of the present invention is to scramble a novel pyrazo mouth [1,5-a] pyridi / ⁇ conductor or a medically acceptable salt thereof useful as ⁇ - ⁇ 2.
- the object of the present invention is a novel MA PKAP-K2, which is a novel neurodegenerative neurological disorder (including dementia), depletion, autoimmune disease, stone 3 ⁇ 43 ⁇ 4 bone disorder, inflammation ' ffl ⁇ disease, psoriasis, diabetes, cancer, ischemia report disorder, angiogenic P territory, cachexia, lunar E3 ⁇ 4 disease, angiogenesis, asthma and / or chronic closure (COPD) « Or to prevent it.
- an object of the present invention is to identify a novel intermediate of MAPKAP-K2P and a novel. '
- the inventors of the present invention have demonstrated that the new pyrazo mouth [1, 5-a] pyridi-conductors represented by the following formula (I) and their pharmaceutically acceptable salt strength are excellent MAPKAP-K2P And the present invention was found to show harmful activity.
- the present invention provides: 1> a pyrazolo [1,5-a] pyridine derivative represented by the formula (I) or a medically acceptable ⁇ &,
- R] represents an optionally substituted CI -C 8 alkenyl group, an optionally substituted C 2 -C8 alkenyl group, an optionally substituted C 2 -C 8 alkynole group, or an optionally substituted C 6 -C 14 aromatic hydrogenated group, optionally substituted aromatic ring group, optionally substituted C 7 -C 16 aromatic hydrogenated alkyl group, optionally substituted aromatic group
- a cyclic alkyl group, an optionally substituted C 3 -C 8 alicyclic ring represents an elementary group, or an optionally substituted alicyclic group.
- R 1 is a halogen atom, a cyano group, a nitro group, an optionally substituted CI-C8 alkyl group, an optionally substituted C3-C8 alicyclic group, or an optionally substituted Resin alicyclic group, C 6-which may be substituted.
- R lx (X represents a, b, c, d, e, f, g, h, i, j, k, 1, m, or n) may be the same or different and is a hydrogen atom, substituted CI -C8 alkyl group (two C 1 -C 8 alkyl groups on one nitrogen atom are bonded via an oxygen atom, nitrogen atom, sulfur atom, or single bond) May be combined with each other to form a ring.
- C 6-C 14 aromatic hydrogenated group optionally substituted aromatic ring group, optionally substituted C 3-C 8 alicyclic ring ⁇ ⁇ is a group, substituted An alicyclic ring group that may be substituted, a C7-C16 aromatic hydrocarbon alkyl group that may be substituted, an aromatic ring alkyl group that may be substituted, or an alicyclic group that may be substituted.
- Ri may be replaced C 6-C14 Yoshi! «I will be a good aromatic unto heterocyclic group originally or substituted.
- R 1 substituents of R ⁇ are two or more bonds, these substituents, an oxygen atom, a nitrogen A ring may be bonded to each other through an atom, a sulfur atom, or a single bond. .
- R 2 is a hydrogen atom, an optionally substituted CI-C8 alkylene group, an optionally substituted C2-C8 alkenyl group, an optionally substituted C2-C8 alkynyl group, substituted C 6 -C 14 fluorinated group, optionally substituted fluorinated ring group, optionally substituted alicyclic group, optionally substituted C 7 -C 16 fluorinated alkyl group Represents a C 3 -C 8 alicyclic group which may be substituted, or an aromatic male ring alkyl group which may be substituted;
- R 2y (y represents a, b, c, d, e, f, g, h, i, j, k, 1, m, or n.) May be the same or different, a hydrogen atom, CI-C8 alkyl group which may be substituted (When two C 2 -C 8 alkyl groups are bonded to one nitrogen atom, oxygen atom, nitrogen atom, sulfur atom , Or may be bonded to each other via a single bond to form a ring.)
- the optionally substituted C 6 -C 14 aromatic ring is an elementary group, an optionally substituted aromatic ⁇ -element ring group, C 3-which may be replaced.
- 8 represents an alicyclic hydrogen halide group, an optionally substituted alicyclic group, an optionally substituted C7-C16 hydrogenated alkyl group, or an optionally substituted aromatic ring alkyl group.
- R2 is an optionally substituted aromatic chain of C 6 -C 14 is a prime group or an optionally substituted aromatic ring group, and R 2 has two or more substituents of R 2. : ⁇ , These substituents may be bonded to each other through an oxygen atom, a nitrogen atom, a sulfur atom, or a simple ring.
- R 3 represents an optionally substituted C 1 -C 8 alkyl group, an optionally substituted C 3 -C 8 alicyclic hydrocarbon group, or an optionally substituted alicyclic group.
- R 3 is a halogen atom, a cyano group, a nitro group, -OR 3a , -SR 3b , -NR 3c R 3 d , an optionally substituted CI-C 8 alkyl group, or an optionally substituted C 3-C8 alicyclic hydrogenation group and one or more substituents selected from the group consisting of an optionally substituted aliphatic ⁇ -element cyclic group.
- R z (z represents a, b, c, or d.) May be the same or different, and may be a hydrogen atom or an optionally substituted CI-C8 alkyl group (2 on one nitrogen atom).
- C 1-C which is R 3 z When 8 alkyl groups are bonded, they may be bonded to each other through an oxygen atom, a nitrogen atom, a sulfur atom, or a single bond to form a ring.
- the substituents of the substituents R ′, R 2 and R 3 are not particularly specified, and are a halogen atom, a hydroxyl group, a cyano group, a nitro group, an amino group, an oxo group, a carboxyl group, a trifluoro group.
- CI-C8 alkyl group which may be converted with a methyl group, a pentafluoroethyl group, a trifluoromethoxy group, (a halogen atom, a hydroxyl group, a cyano group or an oxo group), (a methyl group, May be substituted with a halogen atom, a hydroxyl group, a cyano group, or an oxo group) and may be substituted with a C 3 -C8 alicyclic hydrogen group (a halogen atom, a hydroxyl group, or a cyano group) C1-C8 anorecoxy group, (methyl group, halogen atom, hydroxynore group, or cyano group) C3-C8 alicyclic hydrogenoxy group, (methyl group, halogen atom, hydro Kisil , Or cyano group) may be substituted with an alicyclic M group, (methyl group, halogen atom, hydroxynor
- 2> 'R] is an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C8 alkenyl group, an optionally substituted C2-C8 alkynyl group, substituted May be C 6-C 14 ⁇ ⁇ ⁇ is a basic group, substituted!
- R lx (X represents a ⁇ b, c, d, e, f, g, h, i, j, k, 1, m, or n) Force may be the same or different, hydrogen atom, substituted CI-C8 alkyl group (when two R lx C 1 -C 8 alkyl groups are bonded on one nitrogen atom, an oxygen atom, nitrogen atom, sulfur atom, or single bond Or a C6-C14 aromatic hydrocarbon group which may be substituted, an aromatic ring group which may be substituted, or C which may be substituted 3-C8 alicyclic ring, hydrogenated group, may be substituted resin group, may be substituted C7-C16 fragrance; alkyl group, hydrogenated alkyl group, optionally substituted 3 ⁇ 43 ⁇ 43 ⁇ 4 Represents an alicyclic alkyl group, or an alicyclic alkyl group which may be substituted; However, the optionally substituted C 6 -C 14 aromatic hydrocarbon is an elementary group
- R 2y (y represents a, b, c, d, e, f, g, h, i, j, .k, l, m, or n) may be the same or different, a hydrogen atom, CI-C8 alkyl group which may be substituted ( ⁇ is a combination of two R2y C1-C8 alkyl groups on one nitrogen atom, oxygen atom, nitrogen atom, sulfur atom, Alternatively, they may be bonded to each other via a single bond to form a ring.)
- the optionally substituted C 6 -C 14 aromatic carbon is a basic group, and may be a monocyclic ring Group, an optionally substituted C 3 -C 8 alicyclic group, an optionally substituted alicyclic group, an optionally substituted C 7 -C 16 haloalkyl alkyl group, or a substituted group Represents an optionally substituted aromatic ring alkyl group;
- R 2 is an optionally substituted C 6 -C 14 aromatic group is a prime group or an optionally substituted aromatic ring group, and R 2 has two or more substituents of R 2.
- ⁇ may be replaced by an oxygen atom, a nitrogen atom, a sulfur atom, or a single bond to form a ring;
- R 3 represents an optionally substituted CI-C 8 alkyl group, an optionally substituted C 3 -C 8 alicyclic hydrocarbon group, or an optionally substituted alicyclic group, a 5-month alicyclic group. Representation;
- R 3 is a halogen atom, cyano group, nitro group, -OR 3a , -SR 3b , -NR 3c R 3 ⁇ optionally substituted CI-8 alkyl group, optionally substituted C3 - ⁇
- R 3z (z represents a, b, c or d) may be the same or different hydrogen atom, optionally substituted CI-C 8 alkyl group (two R 3Z on one nitrogen atom)
- the C 1 -C 8 alkyl group is bonded to each other through an oxygen atom, a nitrogen atom, a sulfur atom, or a single atom to form a ring.
- R ′, R 2 and R 3 are a halogen atom, a hydroxy group, a cyan group, a nitro group, an amino group, a (halogen atom, a hydroxyl group, a cyan group, or an oxo group).
- C 1 -C8 alkyl group (a methyl group, a halogen atom, a hydroxy group, a cyano group, or an oxo group) may be substituted with an alicyclic ring of C3 -C8 CI-C8 alkoxy group, which may be substituted with a hydrogen group, rhe, a rogen atom, a hydroxyl group, or a cyano group, or a methyl group, a halogen atom, a hydroxyl group, or a cyano group may be substituted with C3-C8 cycloaliphatic hydroxoxy group, (methinole group, halogen atom, hydroxyl group, or cyano group) optionally substituted alicyclic ring group, (methyl group, halogen atom, hydroxyl group, or cyclo group) Selected from a C 6 -C 14 aromatic hydrogenated group that may be substituted with a cyan
- R 2 is S-substituted or CI, C 6 -alkyl group substituted by R, rogen atom, hydroxyl group, or -NR 2c R 2d ), or substituted C 3-C 7
- the alicyclic group is an elementary group (R 2c or R 2d may be the same or different and each is independently a hydrogen atom, an unsubstituted or C1-C6 alkyl group substituted with a fluorine atom, or Substituted C 3 -C 7 alicyclic hydrogen group); powerful R 3 is unsubstituted C 1 -C 6 alkyl group:
- R 1 is an unsubstituted C 1 -C 6 alkyl group, or a phenyl group that is unsubstituted or substituted with a halogen atom; ⁇ 2 unsubstituted or (halogen, -OH or, - NR 2c R 2d) in the substituted C 1 - C 6 alkyl group or unsubstituted C 3, - C 7 cycloaliphatic ⁇ I originally (R 2c Or R 2d may be the same or different from each other, and may be a hydrogen atom, an unsubstituted or fluorine-substituted C 1 -C 6 alkyl group, or an unsubstituted C 3 -C 7. ; Force, R 3 is a C 1 -C 6 alkyl group substituted or substituted with a fluorine atom, or ⁇ tt-substituted C 3 -C 7 alicyclic group:
- R 3 is a fluorine atom or a CI-C 8 alkyl group substituted by other than -OR 33 , a substituted C 3 -C 8 alicyclic group is a basic group, or a substituted fatty acid; ⁇ or 1 or a pyrazo mouth [1, 5-a] pyridi described in ⁇ 2>; or a conductor or a medically acceptable salt thereof; 5> R 1 is substituted.
- CI-C 8 anoalkyl group which may be substituted C 6 -C 14 aromatic hydrocarbon group which may be substituted, aromatic ring group which may be substituted, C 7 which may be substituted -C 16 is an aromatic group, an optionally substituted aromatic silicon ring alkyl group, or an optionally substituted C3-C8 alicyclic group, 1> to 4>
- the pyrazo mouth according to any one of [1, '5-a] pyridi ⁇ conductor or a medically acceptable salt thereof,
- R 1 is an optionally substituted C 1 -C 8 alkyl group, an optionally substituted C 6 -C 14 aromatic group is an elementary group, or an optionally substituted aromatic ring group.
- R 1 is an optionally substituted C6-C14 aromatic group is an elementary group or an optionally substituted aromatic ring group, ⁇ 1> to 4>
- R 1 is an optionally substituted aromatic ring group, and the pyrazolo [1, 5-a] pyridi / f
- R 1 has a structure in which an aromatic ring of ⁇ which may be substituted with a phenyl group is formed, and the phenyl group side is a pyrazolo [1, 5-a] pyridine of the formula (I)
- R ' is an optionally substituted C7-C16 fragrance; ⁇ an alkyl group or an optionally substituted aromatic ring alkyl group, wherein any of ⁇ 1> to 4>
- R 1 is a fluorine atom, a chlorine atom, a cyano group, a nitro group, an optionally substituted C 1 -C 6 alkyl group, an optionally substituted C 3 -C 8 alicyclic ring ⁇
- a hydrogenated group an optionally substituted C1-C6 anorecoxy group, an optionally substituted C1-C6 alkylthio group, an optionally substituted phenyl group, an optionally substituted aromatic ring group, CI-C6 acyl group which may be substituted, amino-amino group of CI-C6 which may be substituted, aminosulfonino group which may be substituted (two alkyl groups are substituted on the aminosulfonyl group)
- Each may be the same or different and may be bonded to each other through an oxygen atom, nitrogen atom, sulfur atom, or a single bond to form a ring.
- R is a fluorine atom, chlorine atom, cyano group, nitro group, optionally substituted C1-C6 alkylthio group, optionally substituted C1-C6 acyl group, substituted A C1-C6 acyloleamino group, an optionally substituted aminosulfonyl group (if the aminosulfonyl group is substituted with two alkyl groups, they are the same or different in three worms, respectively) Preferably, they may be bonded to each other through an oxygen atom, nitrogen atom, sulfur atom, or single bond to form a ring.)), Optionally substituted C 2 -C 7 alkoxycarbonyl group, substituted A sulfonylamino group which may be substituted, and a canolevamoinole group which may be substituted (wherein the two alkynole groups are substituted on the canolemominole group, each may be the same or different, and an oxygen atom
- R 1 is a fluorine atom, atom, Shiano group, a nitro group, an optionally substituted phenyl group, and it may also be substituted with one or more selected from the group consisting of aromatic heterocyclic groups Or a medically acceptable salt thereof.
- R 1 is a substituent selected from the group consisting of (an optionally substituted phenyl group and an optionally substituted aromatic ring group), and (fluorine atom, crane Atom, cyano group, and nitro group) It can contain one or more substituents selected from the group consisting of: 1> to 11>, and the displacement force described in the pyrazo mouth [1, 5-a ] Pyrigi conductor or its medically acceptable ⁇ &,
- R 1 is substituted with a fluorine atom, a «atom, a cyano group, (one or more substituents selected from the group consisting of a nodular gen atom, a hydroxy nore group, and a cyano group) C1-C6 alkyl group, which may be substituted with one or more selected from the group consisting of a halogen atom, a hydroxyl group, and a cyano group C3-C8 alicyclic hydrogen group CI-C6 alkoxy group or (methyl group, halogen atom, optionally substituted by one or more substituents selected from the group consisting of,, and Gure, logon atom, hydroxyl group, and cyano group)
- One or more substituents selected from the group consisting of a hydroxyl group, a cyano group, and an oxo group may be substituted with a C 3 -C6 alicyclic T-oxy group) and substitute
- C 1 -C 6 alkynole group optionally substituted with R 1 in place of [one or more substituents selected from the group consisting of rhe, a rogen atom, a hydroxyl group, and a cyano group] , C, C 3 -C 8 alicyclic hydrogen groups, and ⁇ R, and may be substituted with one or more positions selected from the group consisting of: a hydrogen atom; a mouth atom atom; a hydroxyl group; Rogen atom, hydroxyl group, and A c 1 -c 6 alkoxy group, which may be converted by selection from the group consisting of an amino group (i or more substituents), or (methyl group, halogen atom, hydroxyl group, cyan group, and CI-C 6 alkyl group substituted with C 3 -C 6 alicyclic ⁇ element oxy group ⁇ which may be substituted with one or more substituents selected from the group consisting of oxo groups]
- Substituent force of R 1 [ ⁇ one or more substituents selected from the group consisting of a carboxyl group, an oxo group, and les, a rogen atom, a hydroxy group, and a cyan group)
- An aromatic ⁇ -element ring group which may be substituted with one or more substituents selected from the group consisting of groups, or one selected from the group consisting of a methylol group, a halogen atom, a hydroxyl group, and a cyan group
- CI-C6 alkyl group which may be substituted with an alicyclic group which may be substituted with the above-described substituent group
- R 1 is a C 1 -C 6 alkyl group that may be substituted with m 1 (one or more substituents selected from the group consisting of a halogen atom, a hydroxyl group, and a cyano group).
- R 1 may be replaced with one or more positions selected from the group consisting of a fluorine atom, a chlorine atom, a cyano group, (a halogen atom, a hydroxy group, and a cyano group) C 1 -An alkoxy group of C 6, (one or more substituents selected from the group consisting of a methinore group, a halogen atom, a hydroxyl group, and a cyano group) ' A C 1 -C 6 alkoxy group, and (one or more substituents selected from the group consisting of a halogen atom, a hydroxyl group, and cyanophane) or a C 1 -C 6 alkoxy group or C 1 -C 6 alicyclic hydrogenated hydroxy group ) C 1 -C 6 alkoxy group 3 ⁇ 4 Pyrazo mouth [1, 5-a] Pyridi ⁇ conductor or its medically acceptable one, which is one or more substituents selected
- C6 moon ring bz element oxy group ⁇ substituted with a C1-C6 anorecoxy group] is one or more substituents selected from the group consisting of: and (a fluorine atom, a chlorine atom, and Pyrazo mouth [1,5-a] pyridi ⁇ conductor or medically thereof according to any one of ⁇ 1> to ⁇ 11>, which may contain one or more substituents selected from the group consisting of: Acceptable salts,
- R 1 may be substituted with [ ⁇ canolepoxyl group, oxo group, and (one or more substituents selected from the group consisting of a halogen atom, a hydroxyl group, and a cyano group)] -One or more substituents selected from the group consisting of alkoxy groups of C 6 ⁇ , which may be substituted with C 1 -C 6 ananoloxy group, and (from methyl group, halogen atom, hydroxyl group, and cyan group)
- the substituent of R 1 is a CI—C 6 alkoxy group which may be substituted with (one or more substituents selected from the group consisting of a halogen atom, a hydroxyl group, and a cyano group), 1> to 1 1>
- the pyrazo mouth [1, 5-a] pyridine derivative or a medically acceptable salt thereof according to any one of
- R 2 is a hydrogen atom, an optionally substituted CI-C8 alkyl group, an optionally substituted C 2 -C 8 alkenyl group, an optionally substituted C 6 -C 14 hydrogenated hydrogen atom
- the group may be substituted! C 7-C 16 aromatic carbon group that may be substituted t ⁇ K group alkyl group, may be substituted, aromatic group alkyl group, or may be substituted C 3-08
- the alicyclic ring is a basic group, and the pyrazo mouth [1, 5-a] pyridiconductor or a medically acceptable salt thereof according to any of the following:
- R 2 is a hydrogen atom, an optionally substituted CI-C6 alkyl group, an optionally substituted C 2 -C 6 alkenyl group, an optionally substituted C 6 -C 14 fragrance TK group, optionally substituted aromatic ring group, optionally substituted C 7 -C 12 phenylalkyl group, or optionally substituted C 3 -C 6 alicyclic ring ,
- a villazolo [1, 5-a] pyridine derivative or a medically acceptable salt thereof according to any one of ⁇ 1> to ⁇ 24>.
- R 2 is a hydrogen atom, an optionally substituted CI-C6 alkyl group, an optionally substituted C2-C6 alkenyl group, or an optionally substituted C3-C6 alicyclic ring ⁇
- R 2 is an optionally substituted C1-C6 alkyl group or an optionally substituted C2-C6 alkenyl group, and any one of ⁇ 1> to ⁇ 2'3>
- R 2 is a hydrogen atom, ⁇ 1> to ⁇ 23>, the pyrazo mouth [1, 5-a] pyridi / «I conductor or a medically acceptable salt thereof according to any one of
- R 2 is a phenyl group which may be substituted or an aromatic heterocyclic group which may be substituted; Pyridi conductor or its medically acceptable salt,
- R 2 substituent is a halogen atom, a cyano group, a nitro group, a hydroxyl group, an optionally substituted amino group (if the amino group is substituted with two alkyl groups, respectively: ⁇ May be the same or different, and may be bonded to each other through an oxygen atom, a nitrogen atom, a sulfur atom, or a single bond to form a ring.
- Alkyl group> may be substituted C'l-C6 ananoloxy group, may be substituted CI-C6 acyl group, may be substituted aminosulfonyl group (the aminosulfonyl group has two alkyl groups
- ⁇ may be the same or different for each of the three worms, and may be bonded to each other through an oxygen atom, nitrogen atom, sulfur atom, or single bond to form a C ring, ),
- An optional canolemomoire group when two alkyl groups are substituted on the canolemoinole group, they may be the same or different, respectively, through an oxygen atom, a nitrogen atom, a sulfur atom, or a single bond.
- the substituent of R 2 is a halogen atom, a cyan group, a nitro group, a hydroxyl group, an amino group that may be substituted (the two alkyl groups are substituted on the amino group, respectively) May be the same or different, and may be bonded to each other through an oxygen atom, a nitrogen atom, a sulfur atom, or a single bond to form a ring.
- a C 6 acyl group, and an optionally substituted canolevamoinole group (in which two alkyl groups are substituted on the canolevainole group, each of which may be the same or different, an oxygen atom, a nitrogen atom, It may be bonded to each other through a sulfur atom or a single bond to form a ring.)
- One or more substituents selected from the group of forces 24> to 30> The pyrazo mouth [1, 5-a] pyridine according to any one of Conductor or a medically acceptable salt thereof, '
- R 2 substituent is a halogen atom, a cyano group, a nitro group, a hydroxyl group, or an amino group that may be substituted. Or they may be the same or different and may be bonded to each other through an oxygen atom, nitrogen atom, sulfur atom, or single bond to form a ring. And 1 or more substituents selected from the group consisting of an optionally substituted C1-C6 alkoxy group, and a deviation of 1> to 4>, 24> to 30>.
- R 3 is an optionally substituted C1-C8 alkyl group, an optionally substituted C3-C8 alicyclic hydrogen group, or an optionally substituted aliphatic ring group. 1> ⁇ 33> les, gaps: Pilazo mouth as described [1, 5-a] Pyridi conductor or its medically acceptable salt,
- R 3 is an optionally substituted C3-C8 lunar cyclized hydrogen group, or may be substituted (aliphatic heterocyclic group having 1 to 4 nitrogen atoms as a heteroatom).
- the pyrazo mouth [1, 5-a] pyridine derivative or a medically acceptable salt thereof, ⁇ 36> wherein R 3 is optionally substituted of C5-C6 ⁇ 1> to ⁇ 33> are either an alicyclic hydrogenated group or an optionally substituted (piperidyl, pyrrolidinyl, or hexahydroazepinyl group) [1, 5- a] Pyridi ⁇ conductor or a medically acceptable salt thereof, ⁇ 37> R 3 is an optionally substituted cyclohexyl group, an optionally substituted piperidyl group, or an optionally substituted pyrrolidinyl group.
- the pyrazo mouth according to any of ⁇ 1> to ⁇ 33> ⁇ [1, 5-a] Pyridi
- the substituent of R 3 is a fluorine atom, a hydroxyl group, a cyano group, an optionally substituted C1-C6 alkyl group, and an optionally substituted amino group (two alkyl groups are placed on the amino group). May be the same or different from each other, and may be bonded to each other through an oxygen atom, a nitrogen atom, a sulfur atom, or a single bond to form a ring.
- the substituent of R 3 is a boron atom, a hydroxyl group, a cyano group, an amino group which may be substituted (the two amino groups are substituted on the amino group, respectively, May be the same or different, and may be bonded to each other through an oxygen atom, nitrogen atom, sulfur atom, or single bond to form a ring.), An amino group which may be substituted (the amino group) Two alkyl groups may be substituted on the radicals, which may be the same or different from each other, and can be linked to each other through an oxygen atom, nitrogen atom, sulfur atom, or single bond!
- the C 5 -C 6 alicyclic ring which may be substituted with) is an elementary group, and (C 1 -C 6 alkyl group which may be substituted with a fluorine atom or a hydroxy group) May be substituted with (piperazino group, piperidyl group, or pyrrolidinyl group),
- substituents selected from the group consisting of: [1] to [4], ⁇ 34> to ⁇ 39> Medically acceptable salt, ⁇ 42> pyrazo mouth represented by formula (6) [1, 5-a] pyridi ⁇ conductor or salt,
- R 1 and R 2 are as defined in formula (I).
- P represents an amino-protecting group.
- R 1 and R 2 are as defined in formula (I).
- Boc represents tert-butoxycarbonyl.
- R 1 and R 2 are as defined in formula (I).
- Boc represents rt-butoxycarbole
- Tf represents trifnoleolomethanesulfonyl.
- R ′, R 2 and R 3 are as defined in formula (I).
- P represents a protecting group for the mino group.
- Boc represents tert-butoxycanoreboninole.
- Karaku 41> includes a pyrazo mouth [1, 5-a] pyridine conductor or a medically acceptable salt thereof, and a pharmaceutically acceptable carrier. Medical, ⁇ 53> ⁇ 1> to ⁇ 41> of the pyrazo mouth [1, 5-a] Pyridi: / t conductor or a medically acceptable salt thereof as a component, MAPKAP-K2P and ⁇ lj,
- the autoimmune female disease is rheumatoid arthritis, ankylosing chronic inflammation, juvenile rheumatoid arthritis, erosive arthritis, unilateral host disease, diabetes or Crohn's disease.
- a therapeutic or prophylactic agent for Brief Description of Drawings is rheumatoid arthritis, ankylosing chronic inflammation, juvenile rheumatoid arthritis, erosive arthritis, unilateral host disease, diabetes or Crohn's disease.
- Figure 1 is an illustration of the p38 MAP K cascade. Best Mode for Carrying Out the Invention ''
- C1-C8 alkyl as used herein represents both caged or branched alkyl groups having 1 to 8 carbon atoms. As not limited to these. For example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butinole, isobutinole, tert-butinole, n-pentinole, isopentinole, neobe: / til, tert-pentyl, 2-methinorepentyl, 4-methylpentyl, 3'-hexyl, n-hexyl, n-heptyl, 2-methylhexynole, 5-methylhexynole, 2-methyl-2-hexyl, 6-methylenoheptyl, or n- Octino.
- alkyl group having 1 to 6 carbon atoms Preferred is an alkyl group having 1 to 6 carbon atoms. More preferred are alkyl groups having 1 to 4 carbon atoms, including, but not limited to, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-petitanol, isobutyl , Or tert-Butino! ⁇ .
- C2-C8 alkenyl means a straight-chain alkenyl group having 2-8 carbon atoms.
- Non-limiting examples include, for example, vinyl, allyl, 1-propenyl, 2-butul, 3-butul, 2-methinole-1-probenole, 4-pentul, 5-hexenyl, or 4 -Metinore-3 -Pentenino.
- Preferred is an alkenyl group having 2 to 6 carbon atoms.
- it is an alkenyl group having 2 to 4 ′ carbon atoms, and examples thereof include, but are not limited to, vinyl, arnanol, isopropenyl, 1-propenyl, 2-butenyl, 1-butenyl, Or 2-methinole-1-probenino.
- C 2 -C 8 ′ alkynyl means a straight-chain alkynyl group having 2 to 8 carbon atoms.
- Non-restricted examples include, for example, Echel-propargyl, 3-methylprono. Noregil, 1-butynyl, 2-butyne-1-yl, Examples include pentynyl and hexynino ⁇ .
- An alkynyl group having 2 to 6 carbon atoms is preferred. More preferably, it is an alkynyl group having 2 to 4 carbon atoms, and examples thereof include, but are not limited to, ethynyl, propargyl, 1-propyl, 1-butynyl and the like.
- a “C 3 -C 8 alicyclic ring” may be partially unsaturated or an alicyclic ring having 3 to 8 carbon atoms that may be saturated. It means a hydride group.
- Non-limiting examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclopenteninole, cyclohexenole, cyclohexenole, cycloheptyl, or cyclo-pure cutino.
- An alicyclic hydrogen group having 3 to 6 carbon atoms is preferred.
- Non-limiting examples include cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexino ⁇ .
- a “C 6 -C 14 aromatic hydrocarbon” contains one ring, or one or more (condensed to an lk sum or unsaturated ring).
- Aromatic carbons having 6 to 14 carbon atoms including, but not limited to, phenyl, naphthyl, anthracenyl, 5-indanyl,., Or 5,6,7,8-tetrahydro -2 -Naphtino, preferably an aromatic having 6 to 6 carbon atoms: a hydrofluoric group, including but not limited to, for example, phenyl, naphthyl, or 5-indanino L More preferably, it is a phenyl group or the like.
- aromatic ring J has 1 to 4 atoms selected from the group consisting of an oxygen atom, a sulfur atom, and a nitrogen atom as a heteroatom, and an aromatic heterocyclic ring.
- examples include, but are not limited to, furan, thiophene, .pyrrole, oxazole, thiazole, isothiazole, imidazole, pyrazole, triazole, thiadiazonole, oxadiazomonore, tetrazonole, pyridine, pyrazine, pyrimidine, pyridazine , Benzofuran, dibenzofuran, benzothiophene, indole, benzimidazole, benzothiazole, benzoxazol, quinoline, isoquinoline, quinazoline, quinoxaline, purine, pteridine, phenoxazine, phenothiazine, a And monovalent cocoon
- Non-limiting examples include, for example, piperidine, pyrrolidine, pyrroline, tetrahydrofuran, dihydropyran, hexahydroazepine, piperazine, quinuclidine, monoreforin, zymophorin, oxazoline, dioxane, pyran, 2-pyrroline.
- piperidine pyrrolidine
- pyrroline tetrahydrofuran
- dihydropyran hexahydroazepine
- piperazine quinuclidine, monoreforin, zymophorin, oxazoline, dioxane, pyran, 2-pyrroline.
- -c] pyridine 1, 2, 3, 4 -tetrahydro.
- [2, 7] naphthyridine, 4, 5, 6, 7 -tetrahydrothiazolo [5, 4-c] pyridine, or 5, 6, 7, 8 -Tetrahydropyrido [4,3-d] pyrimidines and the like include 3 ⁇ 4 ⁇ .
- a 'hetero atom it contains at least one nitrogen atom:! ⁇ 3 heteroatoms, may be partially unsaturated, or may be saturated Fat means a heterocycle.
- Non-limiting examples include piperidine, pyrrolidine, pyrroline, hexahydroazepine, piperazine, morpholine, or oxazoline. More preferred are piperidine, pyrrolidine, hexahydroazepine, piperazine, or morpholine.
- aromatic alkyl ether is a group of a combination of a fluorinated hydrogen and an alkyl group.
- Non-limiting examples include benzyl, vinylene, (2-naphthyl) methyl, 3-phenylpropyl, 4-phenylbutyl, or 5- (1-naphthyl) pentino.
- it is a fragrance; a group in combination with an alkyl group having 1 to 4 carbon atoms having phenyl as a b ⁇ k element, and examples thereof include benzyl, phenethyl, 3 -Phenylpropyl, 4-phenylbutyl, etc. are mentioned.
- aromatic alkyl used in the present specification is a group of an aromatic ring and an alkyl group.
- these are not limited to, for example, 2 -Frinolemethyl, 3 -Frinolemethyl, 2-(2 -Cheninole) ethyl, 2-(3 -Cenyl) propyl, 2 -Methylole-1-( 1-pyrrolinole) propyl, or 1- (2-pyrrolinore) echino! ⁇ .
- aliphatic ring alkyl is a group of a combination of an aliphatic ⁇ ring and an alkyl group ⁇ :. Preferably, it has 1 to 3 atoms selected from the group consisting of ⁇ atom, sulfur atom, and nitrogen atom as a hetero atom, and may be partially unsaturated or saturated. A group consisting of a heterocycle of a group and an alkyl group of 1 to 4 carbon atoms. More preferably, as a non-limiting example, for example, 3-piberidinoremethinole, 3-pyrrolidylmethyl, 2- (4-piperidyl) ethyl, 2- (2-tetrahydrofurinole) propyl, 1-
- C 1 -C 8 alkoxy refers to both straight or branched alkoxy groups having from 1 to 8 carbon atoms, including, but not limited to: For example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, n-pentyloxy, n-hexyloxy, n-heptyloxy and the like can be mentioned.
- Preferred is an alkoxy group having 1 to 6 carbon atoms.
- it is an alkoxy group having 1 to 4 carbon atoms, and examples thereof include, but are not limited to, methoxy, ethoxy, n- propoxy, isopropoxy, n -butoxy, tert-butoxy and the like. It is done.
- cycloaliphatic is an oxy group
- oxy group is a group of the moon and oxy group “ ⁇ :”.
- cyclopropyl Examples include xychi, sucrose / reoxy, stigma pentenoreoxy, stigma pentenorexi, sicca hexenore xi, cyclohexenyloxy, cycloheptyloxy, or cyclooctyloxy.
- C 1 -C 6 alkylthio is a group of a combination of a C 1 -C 6 alkyl and a thio group.
- Non-limiting examples include, for example, methylthio, ethinoretio, n-propino, isopropylthio, n-butinoretio, sec-butinoretio, isobutylthio, tert-butylthio, n-pentylthio, isopentylthio, neopentylthio, tert-pentylthio, Examples include 2-methylpentylthio, 4-methylpentylthio, 3-hexylthio, n-hexinoretio, and n-heptinoretio.
- a thio group having 1 to 4 carbon atoms More preferably, it is a thio group having from 3 to 3 carbon atoms.
- Non-limiting examples include methylthio, ethylthio, n-propinoretio, and isopropylthio.
- C 1 -C 6 isyl J is an alkyl or alicyclic group having 1 to 6 carbon atoms; a hydrogen group having a hydrogen fluoride. Examples include acetyl, propionyl, 7 "tyryl, isobutyryl, valeryl, isovaleryl, or pivaloidino U.
- C 1 -C 6 asinoleamino is a group of C 1 -C 6 asinole and amino group ⁇ :.
- Preferable examples include, but are not limited to, acetylamino, propioninoleamino, butyrinoreamino, isobutyrinoreamino, valerylamino, isovalerylamino, or bivalloylamino.
- C 2 -C 7 alkoxycarbonyl J is a group of C 1 -C 6 alkoxy and carbonyl groups” ⁇ .
- Preferred examples include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, or tert-butoxycarbonyl.
- C 7 -C 12 phenylalkyl is a group of a phenyl and C 1 -C 6 alkyl group ⁇ :.
- benzyl, phenethyl, 2-phenylpropyl 3-phenylpropinole or 4-phenylbutino is a group of a phenyl and C 1 -C 6 alkyl group ⁇ :.
- benzyl, phenethyl, 2-phenylpropyl 3-phenylpropinole or 4-phenylbutino is a group of a phenyl and C 1 -C 6 alkyl group ⁇ :.
- benzyl, phenethyl, 2-phenylpropyl 3-phenylpropinole or 4-phenylbutino is a group of a phenyl and C 1 -C 6 alkyl group ⁇ :.
- amino-protecting group means an amino-protecting group that is widely used in this field (Reference book: Protective Group Synorganic Synthesis, 3fex John Wiley & Sons Inc.) 0
- tert-butoxycarbonyl benzenooxycarbonyl, 1 ⁇ oxycarbonyl, ethoxycarbol, 2, 2, 2-trichloroethoxycarbonyl, acetyl, trifnoleoloacetyl, bivaloyl, benzoyl, 2, 4, 6-trimethylbenzoinole, p -methoxybenzinole, 3, 4 -dimethoxybenzyl, tert -butinole, methoxymethyl, 2-Trimethylino resilino ethoxy methino or benzyloxy methino.
- tert-butoxycarboninole More preferably, for example, but not limited to, for example, tert-butoxycarboninole, benzinore xycanenoboninore, methoxycanoleboninole, ethoxycanonolonyl, or alkoxycarbonyl of 2,2,2-trichloroethyl ethoxycarbonino Nil is raised. More preferred is tert-butoxycarbonyl.
- perfluoroalkylsulfonyl is a fluorine polysubstituted alkylsulfonyl group for converting a hydroxyl group to, which is widely used in this field.
- examples include, but are not limited to, trifluoromethanesulfonyl, or nonafluorobutanesulfonino! ⁇ . More preferably, it is trifunoleolomethanesulfonyl.
- halogen atom j means a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom. Preferably, it is a fluorine atom, a « atom, or a bromine atom, and more preferably Fluorine atom or ⁇ ⁇ 3 ⁇ 4 atom.
- C 1 -C 8 alkyl group (two (R ′ x , R 2 or R 3z ) on one nitrogen atom) CI ⁇
- the C 8 alkyl group may be bonded to each other through an oxygen atom, a nitrogen atom, a sulfur atom, or a single bond to form a ring.)
- Examples thereof include 1-pyrrolidinyl, 2-methyl-1-pyrrolidinyl, 1-piperidyl, morpholino, thiomorpholino, and piperazino.
- Preferred examples include 1-pyrrolidinyl, 1-piperidyl, monoreforino, piperazino and the like.
- an optionally substituted aromatic group of C 6 -C 14 is a basic group or an optionally substituted aromatic ring group, and (the R 1 Or the age when two or more (! ⁇ Or! ⁇ 2 ) substituents are bonded to R 2 ). May combine with each other to form a ring.
- C such as “C 1” represents a carbon atom, and the number attached thereafter represents the number of carbon atoms.
- C 1 -C6j represents a range of carbon number 1 force carbon number 6.
- the carbon number is different, it means“ the group having the carbon number ”.
- C 1 -C 6 alkyl group means an alkyl group defined by “C 1 -C 8 alkyl group” having 1 to 6 carbon atoms. The same applies to the handling of carbon number in other groups.
- R is an optionally substituted CI-C8 alkyl group, an optionally substituted C2-C8 alkenyl group, an optionally substituted C2-C8 alkynyl group, optionally substituted C 6-C 14 aromatic charcoal tTk group, optionally substituted aromatic ⁇ element ring group, optionally substituted C 7-C 16 aromatic hydrogen alkyl group, optionally substituted aromatic A silicon ring alkyl group, an optionally substituted C 3 -C 8 alicyclic hydrogen group, or a substituted alicyclic KM ring group.
- an optionally substituted C 1 -C 8 alkyl group, an optionally substituted C 2 -C 8 alkkeninole group, an optionally substituted C 6 -C 14 aromatized permanent group An optionally substituted aromatic silicon ring group, C7-C16 fluorinated alkyl group optionally substituted, ⁇ -substituted alkyl group optionally substituted, alicyclic hydrogen group of C3-C8 optionally substituted, or substituted This is the alicyclic ring 3 ⁇ 4 ⁇ . More preferably, an optionally substituted C 6 -C 14 aromatic hydrocarbon group, an optionally substituted aromatic ring group, and an optionally substituted C 7 -C 16 aromatic fiber is a prime alkynole group.
- an optionally substituted aromatic ring alkyl More preferably, it may be an optionally substituted C 6 -C 14 aromatic hydrogenated group, or an optionally substituted aromatic ring, and even more preferably, an optionally substituted phenyl group or an optionally substituted Re, aromatic silicon ring.
- the aromatic ring group that may be substituted for R 1 has a structure in which the aromatic carbon of the aromatic group may be substituted with an aromatic group that has an aromatic ring strength S and the aromatic group 3 ⁇ 4 ⁇ It is preferable that the ring side of the element is bonded to the NH group at the 7-position of the pyrazo mouth [1, 5 -a] pyridi-conductor of formula (I).
- aromatic hydrocarbon examples include vinyl.
- Preferred aromatic ring groups include, but are not limited to, for example, benzothiazonol-4-yl, benzothiazonoreno-5-inole, benzothiazonole-6-inole, benzothiazole-7- , Benzoxazonole-4-inole, Benzoxazol-5-Inole, Benzoxazonole-6-yl, Ben Zoxazonole--: Inole, Benzimidazole-4-Inole, Benzimidazole -5 -Y Nore, Benzimidazore-6 -Inole, Benzimidazole-7 -Inole, Indazole-4 -Yil, Indazo-Nore-5 -Yil, Indazo Monore-6 -Inole, Indazole-7-.yl, Benzothiophene'-4-Inole, Benzothiophene-5-yl, Benzothioph
- R 1 , x (X represents a, b, c, d, e, f, g, h, i, j, k, 1, m, or n) may be the same or different, hydrogen atom, substitution CI-C8 alkyl group (two Rlx C1-C8 alkyl groups are bonded on one nitrogen atom: ⁇ , oxygen atom: nitrogen atom, sulfur And may form a ring with each other via an atom or a single bond.), An optionally substituted C 6 -C 14 aromatic group, an optionally substituted aromatic ⁇ -element ring group, C3-C8 alicyclic hydrogen group which may be substituted, alicyclic group which may be substituted, aromatic group of C7-C16 which may be substituted; ⁇ is a prime alkyl group, which may be substituted It represents an aromatic ring alkyl group or an alicyclic KM aromatic ring alkyl group which may be substituted.
- R lx is a hydrogen atom
- an optionally substituted CI - C 1 are two R lx on Anorekinore group (one nitrogen atom of the C 4 - instar alkyl group C 4 are attached , An oxygen atom, a nitrogen atom, a sulfur atom, or a single bond to form a ring together with each other.))
- a C 3 -C 6 alicyclic group which may be substituted is a prime group, a substituted or unsubstituted alicyclic group, an optionally substituted phenylalkyl group, and an optionally substituted aromatic group; !
- R 1 ⁇ is a hydrogen atom, and an optionally substituted CI-C 4 alkyl group (two C 1 -C 4 alkyl groups that are R 1 ⁇ are bonded to one nitrogen atom. ⁇ May be bonded to each other through an oxygen atom, a nitrogen atom, a sulfur atom, or a single bond to form a ring.)) 'Aromatic silicon that may be substituted.
- Ring group may be substituted It represents an alicyclic group, an optionally substituted aromatic ring alkyl group, or an optionally substituted olefin group.
- R 1 is an optionally substituted C6-C14 aromatic group is an elementary group or an optionally substituted aromatic heterocyclic group
- R ′ has two or more substituents of R 1 and a J bond However, these substituents may be bonded to each other through an oxygen atom, a nitrogen atom, a sulfur atom, or a single bond to form a ring.
- R 2 represents a hydrogen atom, an optionally substituted CI-C8 alkyl group, an optionally substituted C2-C8 alkenyl group, an optionally substituted C2-C8 aralkynyl group, or an optionally substituted group.
- Aromatic fibers of C6-C 14 are basic groups, may be substituted ⁇ aromatic ring groups, may be substituted ⁇ aliphatic heterocyclic groups, may be substituted C 7-C 16 fragrances; 'Represents a hydrogen alkyl group, an optionally substituted C3-C8 alicyclic hydrogen group, or an optionally substituted aromatic ring alkyl group.
- a hydrogen atom, an optionally substituted CI-C6 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C6-C14 aromatic hydrogen group may be substituted or aromatic silicon ring groups, or C 3 -C 8 alicyclic hydrogenated hydrogen atoms which may be emulated. More preferably, a hydrogen atom, an optionally substituted CI-C4 alkyl group, an optionally substituted phenyl group, an optionally substituted aromatic ring group, or an optionally substituted C 3 -C 6 The alicyclic element 3 ⁇ 4 ⁇ . Even more preferably, they are a hydrogen atom or an optionally substituted C1-C4 alkyl group.
- R 2y (y represents a, b, c, d, e, f., G, h, i, j, k, 1, m, or n.) May be the same or different, hydrogen C 1 is a two R 2 y in Anorekiru group (on one nitrogen atom of C 8 - - atom, CI be substituted ⁇ C8 alkyl group is bonded, an oxygen atom, a nitrogen atom, sulfur A ring may be bonded to each other via an atom or a single bond.)
- the aromatic group of C6-C14 which may be substituted is a basic group, and an aromatic group which may be substituted is a cyclic group.
- a hydrogen atom, substituted ! may be a CI-C4 anoalkyl group (two R 2 y C 1 -C 4 alkyl groups are bonded on one nitrogen atom: ⁇ is oxygen An atom, a nitrogen atom, a sulfur atom, or a single bond may be bonded to each other to form a ring.),
- An optionally substituted phenyl group, an optionally substituted aromatic ring group The alicyclic ring of C3-C6 which may be substituted is a prime group, an alicyclic group which may be substituted, a phenylalkyl group which may be substituted, or a monocyclic alkyl which may be
- 3 ⁇ 4 represents ⁇ . More preferably, a hydrogen atom, an optionally substituted CI-C4 alkyl group (two R 2 y C1-C4 alkyl groups are bonded to one nitrogen atom is an oxygen atom, nitrogen A ring may be bonded to each other via an atom, a sulfur atom, or a single bond.)
- An aromatic ring group that may be substituted, an alicyclic group that may be substituted, or a ring that may be substituted Represents a good aromatic female ring alkyl.
- R 2 is an optionally substituted C 6 -C 14 aromatic group is an elementary group or an optionally substituted aromatic heterocyclic group, and R 2 has two or more substituents of R 2 Is bound to these substitutions
- the groups may be bonded to each other through an oxygen atom, a nitrogen atom, a sulfur atom, or a single bond to form a ring.
- R 3 represents an optionally substituted CI-C 8 anoalkyl group, an optionally substituted C 3 -C 8 alicyclic 5 ⁇ group, or an optionally substituted alicyclic group.
- the C 3 -C 6 alicyclic ring which may be substituted is a basic group, or a substituted alicyclic ring or an aliphatic silicon ring. More preferably, it is a C 3 -C 8 alicyclic group substituted with an optionally substituted amino group or may be substituted (having 1 to 4 nitrogen atoms as a hetero atom) Alicyclic group) and the like.
- R 3 is a halogen I ⁇ element, a cyano group, a nitro group, -OR 3a , -SR 3b , -NR 3c R 3d , an optionally substituted CI-C 8 alkyl group, or optionally C 3-C 8 (D ⁇ -hydrogen group, and optionally substituted, one or more substituents selected from the group consisting of aliphatic ring groups.
- R 3 is an optionally substituted C 1 -C 8 alkyl group ⁇ , the preferred R 3 position is —OR 3a , —NR 3c R 3d , optionally substituted amino group
- substituents selected from the group consisting of a C3-C8 alicyclic group, a hydrogenated group, and an alicyclic group which may be substituted. Further, in addition to the substituent, it may be substituted with a halogen atom, a cyano group, and 1 to 5 substituents selected from the group consisting of C 1 -C 6 alkyl. ⁇ .
- R 3 may be substituted C1 - alkyl group C 8; ⁇ and more preferred substituents for R 3 are, -OR 3a, _.NR 3c R 3d , it may be substituted with an amino group C5 -C6 alicyclic hydrocarbon group, and optionally substituted (an alicyclic group containing 1 to 2 nitrogen atoms). Further, in addition to the ⁇ group, it may be substituted with 1 to 4 units S selected from the group consisting of a fluorine atom, a cyano group, and an optionally substituted C1-C4 alkyl.
- R 3 may be substituted C 3 -C8 alicyclic is a ⁇ of the primary group, and preferred R 3 substituents are -OR 3a , -NR 3c R 3d , an optionally substituted amino group 1 to 3 substituents selected from the group consisting of a C1-C6 alkyl group which may be substituted with, and an alicyclic group which may be substituted. Further, in addition to the substituent, a halogen atom, a cyano group, and an optionally substituted C 1 -C 6 alkyl are selected from: May be substituted by ⁇ 5 substituents.
- R 3 may be substituted in the C 3 -C 8 cycloaliphatic hydrogen group: ⁇ , and the more preferred R 3 position is -OR 3a , -NR 3c R 3d , or an amino group A C 1 -C 6 alkyl group, and 1 to 2 wisteria groups that may be substituted (an alicyclic group containing 1 to 2 nitrogen atoms). Further, in addition to the above group, it may be substituted by 1 to 4 substituents selected from the group consisting of a fluorine atom, a cyano group, and an optionally substituted C 1 -C 4 alkyl.
- R 3 is an optionally substituted alicyclic group: ⁇ , and preferred R 3 substituents are -OR 3a , -NR 3c R 3d , a halogen atom, a cyano group, an optionally substituted CI- From an alkyl group of C 6, an optionally substituted C 3 -C 8 alicyclic hydrogen, and an optionally substituted aliphatic ring 1 to 5 substituents selected from the group consisting of R 3 may optionally be substituted; more preferred R 3 substituents of 3 ⁇ 4 ⁇ of the M ring group are: —OR 3a , —NR 3c R 3d , fluorine atom, cyano group, substituted 1 to 4 groups selected from the group consisting of a good CI-C 4 alkyl group, an optionally substituted C 3 -C 6 alicyclic ⁇ hydrogenated group, and an optionally substituted alicyclic ring » is there.
- R 3z (z represents a, b, c or d) may be the same or different, a hydrogen atom, an optionally substituted CI-C8 alkyl group (two R on one nitrogen atom)
- the age at which the C 1 -C 8 alkyl group of 3 z is bonded may be bonded to each other via an oxygen atom, a nitrogen atom, a sulfur atom, or a single bond to form a ring. May be replaced C 6-C 14 good! 3 ⁇ 4 Hydrocarbon group, optionally substituted aromatic ring group, optionally substituted C 3-. 8 alicyclic hydrogen radicals, optionally substituted alicyclic radicals, or optionally C 7 -C 16 excellent!
- «I represents a cyanoalkyl group or an aromatic cycloalkyl group that may be substituted.
- R 3z is a hydrogen atom, an optionally substituted CI-C4 alkyl group (two R 3 z CI-C 4 alkyl groups are bonded on one nitrogen atom: tj ⁇ May be bonded to each other through an oxygen atom, a nitrogen atom, a sulfur atom, or a single bond to form a ring)), a phenyl group which may be substituted, a substituted ring, an aromatic ring Group, an optionally substituted C3-C6 alicyclic group, an optionally substituted resin MM alicyclic group, an optionally substituted phenylalkyl group, or an optionally substituted aromatic female ring alkyl Represents ⁇ .
- R 32 is a hydrogen atom, an optionally substituted CI-C 4 alkyl group (two R 3Z C 1 -C 4 alkyl groups are bonded to one nitrogen atom)
- the ring may be bonded to each other through an oxygen atom, a nitrogen atom, a sulfur atom, or a single bond.)
- An optionally substituted aromatic ring group, or an optionally substituted ring group An alicyclic heterocyclic group, or an optionally substituted aromatic ring alkyl group ⁇ represents an aliphatic group.
- ⁇ is a halogen atom, a hydroxy group, a cyano group, a nitro group, an amino group, (1 to 9 b atoms, One or more of the groups selected from the group consisting of 1 to 2 hydroxy groups, 1 to 2 cyanos groups, and 1 to 2 oxo groups may be substituted with C 1 -C8 An alkyl group, (1 to 4 medyl groups,:! To 9 halogen atoms, 1 to 2 hydroxyl groups,:!
- the C 3 -C 8 alicyclic ring which may be substituted with one or more substituents selected from is a basic group, (1 to 9 halogen atoms,:! To 2 hydroxyl groups, and 1 to CI-C8 ananoloxy group, which may be substituted at one or more positions selected from the group consisting of two cyan groups, (1-2 methyl groups, 1-9 halogen atoms, 1-2 ⁇ : Droxyl group, and (One or more substituents selected from the group consisting of 1 to 4 methyl groups, 1 to 8 halogen atoms, 1 to 2 hydroxyl groups, and 1 to 2 cyanos groups) It is composed of a fatty acid, a J ⁇ ring group, (1 to 4 methyl groups, 1 to 5 halogen atoms,:!
- C6-C 14 aromatics that may be substituted with one or more substituents selected from the group; ⁇ hydrogenated groups, and (1 to 4 methyl groups, 1 to 5 halogen atoms, 1 to 2 Selected from the group consisting of 1 hydroxyl group, 'and 1 to 2 cyano groups Or one or more substituents selected from aromatic ring systems.
- substituent of the substituent of R 1 preferably, a halogen atom, a hydroxyl group, an amino group, (1 to 7 fluorine atoms, 1 to 2 hydroxyl groups, !! to 2, / an group , And one or more substituents selected from the group consisting of 1 to 2 oxo groups) C 1 -C 6 alkyl group optionally substituted with (1 to 4 methyl groups,!
- substituents selected from the group consisting of 7 fluorine atoms, 1 to 2 hydroxyl groups, 1 to 2 cyanos group, and 1 to 2 oxo groups) 1-one or more positions selected from the group consisting of 3 to C 8 alicyclic hydrogen groups, (1 to 7 fluorine atoms,:!
- C 1 -C 6 alkoxy groups (1 to 4 methyl groups, 1 to 7 fluorine atoms, ⁇ to 2 hydroxyl groups, and 1 to 2
- the C 3 -C 8 alicyclic ring may be substituted with an oxy group, (1 to 4 methyl groups, 1 to 6 substituents, which may be substituted with one or more substituents selected from the group consisting of cyan groups)
- An alicyclic ring group which may be converted with a fluorine atom, 1 to 2 hydroxyl groups, and: 1 to 1 or more substituents selected from the group consisting of 2 cyan groups) (1 to One or more difficult groups selected from the group consisting of 4 methyl groups, 1 to 5 halogen atoms, 1 to 2 hydroxyl groups, and 1 to 2 cyanos groups).
- the aromatic fiber of C 6 -C 14 is an elementary group, and (1 to 4 methyl groups,:! To 5 halogen atoms,:! To 2 hydroxyl groups, and 1 to 2 cyanos 1 or more substituents selected from the group consisting of a group) and one or more substituents selected from a fluorine ring which may be substituted with a halogen as a substituent of the substituent of R 1 Including atoms, 1 to 8 atoms are preferable, and the substituent m3 ⁇ 4 of R 1 is selected only from the other substituents.
- substituent of the substituent of R 1 more preferably, a halogen atom, a hydroxyl group, an amino group, (1 to 5 fluorine atoms,:! To 2 hydroxy groups, or 2 groups,! To 2 pieces A C 1 -C 4 alkyl group optionally substituted with a cyano group and one or more substituents selected from the group consisting of 1 to 2 oxo groups, (1 to 4 methyl groups, 1 to 7 fluorine atoms,:!
- substituents selected from the group consisting of 2 to 1 hydroxy groups, 1 to 2 cyanosyl groups, and 1 to 2 oxo groups
- C 3 -C 6 alicyclic 3 ⁇ 4 ⁇ hydrogen group selected from the group consisting of (1 to 7 fluorine atoms, 1 to 2 hydroxyl groups, and 1 to 2 cyan groups) C 1 -C 4 alkoxy group (1 to 4 methyl groups,:! To 7 fluorine atoms,:!
- substituent of the substituent of R 2 preferably, a halogen atom, a hydroxyl group, a cyano group, a nitro group, an amino group, (1 to 9 fluorine atoms, 1 to 2 hydroxyl groups, 1 to 2
- a good C 3 -C 8 alicyclic ring is a group selected from the group consisting of a basic group, (1-9 fluorine atoms,:!-2 hydroxyl groups, and 1-2 Cyan groups.
- C 1 -C 6 alkoxy group which may be substituted in the above position, (1 to 4 methyl groups, 1 to 9 fluorine atoms, 1 to 2 hydroxyl groups, and 1 to 2 cyanos
- a C 3 -C 8 alicyclic bTk group oxy group which may be substituted with one or more substituents selected from the group consisting of groups, and (1-4 methyl groups, 1-6 Halogen atom 'At least one position selected from aliphatic ring 3 ⁇ 4 ⁇ which may be substituted with 1 or 2 hydroxyl groups, and 1 or more substituents selected from the group consisting of 1 to 2 cyanos groups) 1 to 8 containing a halogen atom as a substituent of the substituent of R 2, and the substituent of the substituent of R 2 is selected only from the other ⁇ :
- ⁇ is preferably 1 to 3 More preferably, a halogen atom, a hydroxyl group, a cyano group, a nitro group, an amino group
- ⁇ 2 oxo groups C 3 -C 6 alicyclic group which may be substituted by a group, (a group consisting of 1 to 7 fluorine atoms, 1 to 2 hydroxyl groups, and 1 to 2 cyan groups) C 1 -C 4 alkoxy group, which may be substituted with one or more substituents selected from: (1 to 4 methyl groups, 1 to 7 fluorine atoms, 1 to 2 hydroxyl groups) , And:!
- ⁇ 2 amino groups (one or more selected from the group consisting of 1 to 5 fluorine atoms, 1 to 2 hydroxy groups, 1 to 2 cyano groups, and 1 to 2 oxo groups) Selected from the group consisting of a C 1 -C 4 alkyl group (which may be substituted), (1 to 5 fluorine atoms, 1 to 2 hydroxyl groups, and 1 to 2 cyan groups) CI-C4 ananoloxy group optionally substituted with one or more substituents), and (1-4 methyl groups,:!-6 halogen atoms,:!-2 hydroxyl groups, And at least one substituent selected from the group consisting of 1 to 2 cyano groups) and an aliphatic group that may be transferred in the following manner: a substitution of R 2 # ⁇ Containing a halogen atom as the substituent of the group is 1 to 6, and 1 to 2 is preferred until the substituent of R 2 is selected from the other substituents alone.
- substituent of the substituent of R 3 preferably, a halogen atom, a hydroxyl group, an amino group, (1 to 9 fluorine atoms,! To 2 hydroxy group, 1 to 2 cyan group , And 1 to 2 selected from the group consisting of 1 to 2 oxo groups, which may be substituted with one or more positions of CI-C 6, an aralkyl group, (1 to 4 methyl groups, 19 fluorine atoms 1 to 2 or more substituents selected from the group consisting of 2 hydroxyl groups, 1 to 2 cyano groups, and 1 to 2 oxo groups) C 3 -C 8 alicyclic hydrogenated groups, (one or more substituents selected from the group consisting of 1 to 9 fluorine atoms, 1 to 2 hydroxyl groups, and 1 to 2 cyan groups) C 1 -C 6 anoralkoxy group, which may be substituted with (1 to 4 methyl groups, 1 to 9 fluorine atoms, 1 to 2 ′
- One or more thighs selected from the group consisting of 2 methyl groups, ⁇ to 5 fluorine atoms, 1 to 2 hydroxyl groups, and 1 to 2 cyanos groups).
- C 6 -C 14 aromatic hydrogenated hydrogen group and (a group consisting of 1 to 4 methyl groups, 1 to 5 fluorine atoms, 1 to 2 hydroxyl groups, and 1 to 2 cyan groups)
- the number of substituents of the substituent of R 3 is selected from 1 to 8 and other substituents alone ⁇ is preferably 1 to 3. More preferably, the substituent of the substituent of R 3 is a halogen atom , Hydroxyl group, amino group, (1 to 7 fluorine atoms, 1 to 2 hydroxy group,:! To 2 cyano groups, and:!
- a C 1 -C 4 alkoxy group which may be substituted with (1 to 4 methyl groups, 1 to 7 fluorine atoms, 1 to 2 hydroxyl groups, and:!
- C 3 -C 6 cycloaliphatic hydrogenoxy group which may be substituted with one or more substituents selected from the group consisting of Cyan groups, (1 to 4 methyl groups, 1 to 6
- An aliphatic group that may be substituted at one or more positions selected from the group consisting of a fluorine atom, and 1 to 2 hydroxyl groups, and a ⁇ 3 ⁇ 4 ⁇ ring group, (1 to 4 methyl groups, 1 to 5 fluorine atoms)
- a phenyl group which may be substituted with one or more substituents selected from the group consisting of 1 to 2 hydroxyl groups, and (1 to 4 methyl groups, 1 to 5 fluorine atoms, and:!
- ⁇ is two of one or more substituents selected from a good aroma «heterocycle substituted with hydroxyl one or more substituents group selected from the group consisting of) substituents R 3
- substituents R 3 When a halogen atom is contained as a substituent, 1 to 8 are preferable, and when the substituent of the substituent of R 3 is selected only from the other substituents, 1 to 3 is more preferable, and R 3 is more preferable.
- the substituents of the substituents are: a halogen atom, a hydroxyl group, an amino group, (1 to 5 fluorine atoms, 1 to 2 hydroxyl groups A C 1 -C4 alkyl group optionally substituted with one or more substituents selected from the group consisting of a group, 1 to 2 cyano groups, and 1 to 2 oxo groups, (1 to 5 Or a C 1 -C4 alkoxy group optionally substituted with one or more substituents selected from the group consisting of a fluorine atom, 1 to 2 hydroxyl groups, and 1 to 2 cyanos groups 1 or more substituents selected from the group consisting of ⁇ 4 methyl groups, 1 to 6 fluorine atoms, and 1 to 2 hydroxyl groups) And (one or more substituents selected from the group consisting of 1 to 4 methyl groups, 1 to 5 fluorine atoms, and 1 to 2 hydroxyl groups).
- substituents selected from, 6. 1 to 3 ⁇ 4 ⁇ , including a halogen atom as a location «substituents R 3, if only the other substituents Substituents of the substituents of R 3 are selected 3 ⁇ 4 ⁇ Les Shi preferred is 1 ⁇ .2 pieces.
- the definition of ⁇ ⁇ shaku 3 and a set of these preferable ones ", and the combination of these preferable ones :: Compound is preferred.
- ⁇ is included in the molecule.
- it can be converted to medically acceptable ⁇ (salt salt if necessary.
- Such acids include, for example, ⁇ , hydrobromic acid, sulfuric acid, phosphoric acid, and charcoal. Or acetic acid, citrate, malic acid, oxalic acid, liquor, lactic acid, maleic acid, fumaric acid, and methanesulfone acid.
- the compound of the present invention may have an acidic group in its molecule. In this case, it can be converted to a medically acceptable salt if necessary.
- such salts include non-toxic cation salts, such as alkali metal ions such as Na + and K + , anolithic earth metal ions such as Mg 2+ and Ca 2+ , A 1 3+ , Zn Metal ions such as 2+ , or ammonia, triethyl / reamine, ethylenediamine, propanediamine, pyrrolidine, piperidine, piperazine, pyridine, lysine (Ly si ne), choline, ethanolamine, ⁇ ,, ⁇ - Examples thereof include salts with organic S such as dimethylethanolamine, 4-hydroxypiperidine, darcosamine, and ⁇ -methinoleglucamine.
- the compounds according to the invention can contain one, two or more asymmetric carbon atoms, which are included in the present invention as photoisomers and racemates.
- the age of the trans form and cis form of the compound of the present invention includes the trans form and the cis form.
- the pyrazo mouth [1, 5-a] pyridi ⁇ ! Conductor represented by the above formula (I) is, for example, a tautomer represented by the following formula (I I).
- R ] , R 2 and R 3 are as defined for formula (I) above. These tautomers are also encompassed within the scope of the invention.
- the compound of the present invention can be synthesized by the following method.
- R 1 , R 2 and R 3 are as defined in formula (I).
- the conditions such as soot or solvent described in the chemical formula are merely examples as described in the text.
- Each substituent may be protected with an appropriate protecting group as necessary, and may be deprotected at an appropriate stage.
- the abbreviations for substituents,, and solvents in the text or in the table represent the following.
- T f Trifnoleolomethanes norehoninole
- Compound A is converted to mos-substituted malonate in the presence of a suitable ⁇ (eg sodium ethoxide) in a suitable organic solvent (eg ethanol) at 0 ° C.
- a suitable ⁇ eg sodium ethoxide
- a suitable organic solvent eg ethanol
- a compound of formula (6) can be converted from 0 ° C to 140 ° under appropriate (eg, N, N-dimethylaniline) or in an appropriate organic solvent (eg, acetonitrile) or under insoluble conditions.
- an appropriate halogenating agent for example, phosphorus oxynitride
- a solvent in an appropriate ram for example, 1,4-dioxane
- the compound power of the formula (7) can be obtained by carrying out the hydrolysis with an aqueous solution containing an appropriate water (for example, an aqueous solution of sodium hydroxide) within the range of the heat flow.
- a compound of formula (7) can be obtained from 0 ° C under suitable: ⁇ S (eg pyridine) or uncovered in a suitable polar solvent (eg 2 : -propanol) or under anhydrous conditions.
- the compound of formula (8) can be obtained by using an amine represented by ⁇ ⁇ 2 in the range of 140 ° C. '
- the compound of formula (7) is suitable under the presence or absence of ⁇ S (eg triethylamine), under or without the appropriate horn butterfly (eg -N, N-dimethylaminopyridine).
- ⁇ S eg triethylamine
- horn butterfly eg -N, N-dimethylaminopyridine
- a suitable shelf solvent eg, 1,4-dioxane
- P is B oc in the temperature range where the heat at 0 ° C. increases
- 1,4-dioxane eg, aqueous sodium hydroxide
- a compound of formula (9) is suitably activated in a suitable cage (eg pyridine) in a suitable (eg triethylamine); f3 ⁇ 4 under a ⁇ 3 ⁇ 4 range of 0 ° C to 50 ° C.
- the compound of formula (11) can be synthesized by reacting with a liquefying agent (L is Tf: ⁇ is a triflate agent (eg, trifluoromethanesulfone water)).
- the compound of formula (13) can be obtained by TO with an amine derivative represented by NH 2 .
- the compound of formula (9) is converted to the literature (J o u r n a 1 o f Or g a n i c Ch em i s t r y,
- an activating agent for example, bromotris (pyrrolidino) phosphonium hexafluorophosphate or benzotriazol-1-yloxytris (pyrrolidino) phosphonium hexaful
- an activating agent for example, bromotris (pyrrolidino) phosphonium hexafluorophosphate or benzotriazol-1-yloxytris (pyrrolidino) phosphonium hexaful
- the compound of the formula (13) can also be obtained by using an amine derivative represented by (Olophosphate) and R 3 NH 2 . 8) Synthesis of chemical compound of formula (14) from compound of formula (13)
- Formula (13) can be converted into a suitable deprotection reagent (P) in the appropriate machine (eg, dichloromethane) or under conditions of ⁇ ⁇
- a compound of formula (14) can be obtained by using a strong acid (for example, tribrenoreoacetic acid)).
- R ′ to R 3 of the pyrazo mouth [1, 5-a] pyridine derivatives represented by the formulas (5) to (14) are represented by the following formula (I): pyrazole port [1, 5 - a] the preferred groups listed in 1 ⁇ to 1 3 in pyridine derivative, described as preferable groups.
- R′ ⁇ : R 3 and the thread of these preferred ones, and the compounds of these preferred pairs of ⁇ : are represented by the formulas (5) to (14) etc.
- a preparation containing the compound of the present invention or a medically acceptable salt as an ingredient is prepared by using a carrier shaping agent or other additives generally used in pharmaceutical preparations.
- Carriers for preparations ⁇ ! Agents can be solid or liquid, misaligned, eg ⁇ ⁇ , magnesium stearate, starch, tanolec, gelatin, agar, pectin, gum arabic, olive oil , Sesame oil, cocoa butter, and ethylene glycol! ⁇ And other commonly used ones.
- Administration is in the form of oral administration by ⁇ lj, pills, capsules, granules, powders, and inflections, or parenteral administration by aw agents such as intravenous and intramuscular injections, suppositories, etc.
- aw agents such as intravenous and intramuscular injections, suppositories, etc.
- MAPKAP-K2P and useful diseases for which the present invention is useful include neurodegeneration / neurological disorders (including dementia), sepsis, autoimmune disease, fracture 3 ⁇ 4tt bone disorder, inflammation ⁇ disease, «, Diabetes, cancer, ischemia-reperfusion injury, angiogenic disorder, cachexia, moonlitness, angiogenesis, asthma and Z or chronic obstructive ffl disease (COPD)).
- neurodegeneration / neurological disorders including dementia
- sepsis autoimmune disease
- fracture 3 ⁇ 4tt bone disorder inflammation ⁇ disease
- inflammation ⁇ disease «
- Diabetes, cancer ischemia-reperfusion injury
- angiogenic disorder cachexia, moonlitness, angiogenesis, asthma and Z or chronic obstructive ffl disease (COPD)
- COPD chronic obstructive ffl disease
- autoimmune pavement examples include rheumatoid arthritis, ankylosing vaginitis, group rheumatoid arthritis, Wtt arthritis, one-sided sympathy ⁇ disease, diabetes or Crohn's disease. It is done.
- the dose of the compound of the present invention varies depending on the type of disease, administration route, patient age and tt3 ⁇ 4iJ, disease, etc., but is usually 1 to 500 mg / day for each adult.
- Example 2 to Example 8 were synthesized according to the method described in Example 1, using the corresponding starting materials and fabrics.
- N-dimenorea dilin (380 iL) to the product (378 mg) of 5,7-dihydroxy-6-methylvirazolo [1, 5 -a] 'pyridine-4-carbotritrinole (), Suspended in phosphorus oxynitride (2. mL) and won for 3 hours under heated drought conditions.
- ⁇ i was brought to room temperature
- i iij and ⁇ ⁇ were distilled off under EE. After the residue is separated with ethyl acetate and water, it is divided and saturated with sodium carbonate in water, and combined with the aqueous layer.
- Example 10 to Example 16 were formed according to the method described in Example 9, using the corresponding starting material and U. ,
- Example 18 to Example 21 were synthesized according to the method described in Example 17 and using the corresponding starting materials. .
- Example 43 force Example 80 is prepared according to either the method described in (Example 40 and Example 41) or the method described in Example 42, the corresponding starting materials and Synthesized using reagents.
- Example 82 was prepared according to the method described in Example 81, using the corresponding starting materials and compounds.
- 5-(trans-4-aminocyclohexylamino)-7 (2-methinolevenzothiazole-6 -ilamino) pyrazo mouth [1, 5-a] pyridine-4- carbonitryl trifno leo mouth £ ⁇ ⁇ (96) ,
- the compound was dissolved in DMSO to a concentration of SOmmolZL and stored at 120 ° C. This stock solution was sequentially sickled with DMSO to prepare a 200-fold concentrated solution in the required range. Further this with water 1:? A 10-fold concentration solution in the required range was prepared at 0, and each night was used for 5 L for every 50 ⁇ L. A series of all compounds! The final DMSO concentration was maintained at 0.5% throughout. The final concentration range ⁇ ⁇ ⁇ ⁇ L to 0.03 ⁇ mol lL was used for the normal concentration of the compound, but depending on its activity, the concentration was sometimes lower.
- the compound of the present invention is useful as an intermediate in the MAP KA P -K 2 P and IJ sentence.
- a novel MA PKAP ”K 2 blockade or a novel theological disorder (including dementia), ⁇ syndrome 143 ⁇ 4 disease, defeated female , Autoimmune 'knee disease, fractured bone disorder, diabetes, cancer, sputum re-latency disorder, angiogenic disorder, badness, hypertrophy, angiogenesis, asthma, and / or chronic closure (CO PD) It is difficult to cure or prevent drugs. . '''
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0607907A BRPI0607907A2 (pt) | 2005-04-07 | 2006-04-07 | derivado de pirazolo [1,5-a] piridina ou sal do mesmo, composição farmacêutica, inibidor de mapkap-k2, e, agente de tratamento ou prevenção |
AU2006234618A AU2006234618A1 (en) | 2005-04-07 | 2006-04-07 | Pyrazolo(1,5-a)pyridine derivative or medically acceptable salt thereof |
CA002603457A CA2603457A1 (en) | 2005-04-07 | 2006-04-07 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof |
EP06731826A EP1873154A4 (en) | 2005-04-07 | 2006-04-07 | PYRAZOLO [1,5-A] PYRIDINE DERIVATIVE OR MEDICINALLY ACCEPTABLE SALT THEREOF |
JP2007513040A JPWO2006109867A1 (ja) | 2005-04-07 | 2006-04-07 | ピラゾロ[1,5−a]ピリジン誘導体またはその医学上許容される塩 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005111419 | 2005-04-07 | ||
JP2005-111419 | 2005-04-07 | ||
JP2005254677 | 2005-09-02 | ||
JP2005-254677 | 2005-09-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006109867A1 true WO2006109867A1 (ja) | 2006-10-19 |
Family
ID=37087129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/307890 WO2006109867A1 (ja) | 2005-04-07 | 2006-04-07 | ピラゾロ[1,5-a]ピリジン誘導体またはその医学上許容される塩 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1873154A4 (ja) |
JP (1) | JPWO2006109867A1 (ja) |
KR (1) | KR20080002935A (ja) |
AU (1) | AU2006234618A1 (ja) |
BR (1) | BRPI0607907A2 (ja) |
CA (1) | CA2603457A1 (ja) |
TW (1) | TW200716630A (ja) |
WO (1) | WO2006109867A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015510894A (ja) * | 2012-03-16 | 2015-04-13 | アクシキン ファーマシューティカルズ インコーポレーテッド | 3,5−ジアミノピラゾールキナーゼ阻害剤 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001139575A (ja) * | 1999-11-15 | 2001-05-22 | Fujisawa Pharmaceut Co Ltd | 新規ピラゾロピリジン誘導体 |
WO2004026872A1 (en) * | 2002-09-19 | 2004-04-01 | Schering Corporation | Pyrazolopyridines as cyclin dependent kinase inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1495016A2 (en) * | 2002-04-09 | 2005-01-12 | Astex Technology Limited | Heterocyclic compounds and their use as modulators of p38 map kinase |
GB0305559D0 (en) * | 2003-03-11 | 2003-04-16 | Teijin Ltd | Compounds |
ATE478852T1 (de) * | 2005-09-09 | 2010-09-15 | Schering Corp | Neue 4-cyano-, 4-amino-, und 4- aminomethylderivative von pyrazoloä1,5- aüpyridinen, pyrazoloä1,5-cüpyrimidinen und 2h- indazolverbindungen und 5-cyano-, 5-amino- und 5- aminomethylderivative von imidazoä1,2-aüpyridinen,und imidazoä1,5-aüpyrazinverbindungen als inhibitoren der cyclinabhänggen kinase |
-
2006
- 2006-04-07 KR KR1020077025890A patent/KR20080002935A/ko not_active Application Discontinuation
- 2006-04-07 AU AU2006234618A patent/AU2006234618A1/en not_active Abandoned
- 2006-04-07 BR BRPI0607907A patent/BRPI0607907A2/pt not_active IP Right Cessation
- 2006-04-07 TW TW095112463A patent/TW200716630A/zh unknown
- 2006-04-07 EP EP06731826A patent/EP1873154A4/en not_active Withdrawn
- 2006-04-07 CA CA002603457A patent/CA2603457A1/en not_active Abandoned
- 2006-04-07 WO PCT/JP2006/307890 patent/WO2006109867A1/ja active Application Filing
- 2006-04-07 JP JP2007513040A patent/JPWO2006109867A1/ja not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001139575A (ja) * | 1999-11-15 | 2001-05-22 | Fujisawa Pharmaceut Co Ltd | 新規ピラゾロピリジン誘導体 |
WO2004026872A1 (en) * | 2002-09-19 | 2004-04-01 | Schering Corporation | Pyrazolopyridines as cyclin dependent kinase inhibitors |
Non-Patent Citations (1)
Title |
---|
See also references of EP1873154A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015510894A (ja) * | 2012-03-16 | 2015-04-13 | アクシキン ファーマシューティカルズ インコーポレーテッド | 3,5−ジアミノピラゾールキナーゼ阻害剤 |
Also Published As
Publication number | Publication date |
---|---|
TW200716630A (en) | 2007-05-01 |
JPWO2006109867A1 (ja) | 2008-11-20 |
EP1873154A1 (en) | 2008-01-02 |
BRPI0607907A2 (pt) | 2016-11-08 |
CA2603457A1 (en) | 2006-10-19 |
KR20080002935A (ko) | 2008-01-04 |
AU2006234618A1 (en) | 2006-10-19 |
EP1873154A4 (en) | 2010-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11661423B2 (en) | Heterocyclic compounds as RET kinase inhibitors | |
RU2742115C2 (ru) | Гетероциклические соединения в качестве ингибиторов киназы RET | |
JP7358491B2 (ja) | 新規なヘテロトリシクリック誘導体化合物およびその用途 | |
JP5490030B2 (ja) | 縮合複素環誘導体およびその用途 | |
AU2018252251B2 (en) | Compounds useful as RET inhibitors | |
JP6896715B2 (ja) | セピアプテリン還元酵素としてのヘテロアリール誘導体 | |
WO2015022926A1 (ja) | 新規な縮合ピリミジン化合物又はその塩 | |
CA2948589A1 (en) | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors | |
EP2945938A1 (en) | 3-substituted pyrazoles and use as dlk inhibitors | |
KR20130025860A (ko) | Tgf-베타 수용체 키나아제 저해제로서의 헤테로아릴아미노퀴놀린 | |
MX2011009314A (es) | Compuesto de quinoxalina. | |
JP2023513854A (ja) | 大環状化合物およびその使用 | |
TWI762534B (zh) | 作為PI3Kδ抑制劑的咪唑並[1,5-A]吡衍生物 | |
CN115996907A (zh) | 用于癌症治疗的mlh1和/或pms2的抑制剂 | |
JP2022550459A (ja) | ムスカリン性アセチルコリン受容体m4のアンタゴニスト | |
WO2009107767A1 (ja) | H4受容体アンタゴニスト作用を有する新規2環性ピリミジン誘導体 | |
JP6457523B2 (ja) | 医薬組成物のためのスルホキシイミン置換キナゾリン | |
WO2006109867A1 (ja) | ピラゾロ[1,5-a]ピリジン誘導体またはその医学上許容される塩 | |
TW202300485A (zh) | Plk4抑制劑及其用途 | |
JP6479854B2 (ja) | 医薬組成物のためのスルホキシイミン置換キナゾリン | |
CN112851664B (zh) | 吡唑[1,5-a]吡啶-3-腈化合物及其在医药上的用途 | |
CN116600808A (zh) | 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用 | |
CA2948589C (en) | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors | |
CN116462688A (zh) | 芳香稠合环类衍生物及其制备方法和用途 | |
CN101189236A (zh) | 吡唑并[1,5-a]吡啶衍生物或其医学上可接受的盐 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680019527.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007513040 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7329/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006234618 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2603457 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006234618 Country of ref document: AU Date of ref document: 20060407 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006234618 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006731826 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077025890 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2006731826 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0607907 Country of ref document: BR Kind code of ref document: A2 Effective date: 20071005 |